Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

SER

Live52w low +23.8%

Annual Quarterly

Core line items from SER's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: Serina Therapeutics, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$0.00	$130.00K	$130.00K	$130.00K	$0.00
Operating Income	Not available	$-24.02M	$-17.82M	$-11.42M	$-5.86M
Net Income	Not available	$-19.18M	$-15.85M	$-11.26M	$-4.81M
EPS (Diluted)	$-0.35	$-1.91	$-1.60	$-1.15	$-0.49
Total Assets	Not available	$6.95M	$12.41M	$8.94M	$6.73M
Total Liabilities	Not available	$6.99M	$10.82M	$7.29M	$5.17M
Cash & Equivalents	Not available	$3.06M	$8.62M	$6.04M	$4.27M
Free Cash Flow OCF − CapEx	Not available	$-18.01M	$-11.98M	$-8.12M	$-4.32M
Shares Outstanding	Not available	10.77M	10.54M	10.14M	9.93M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from SER's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +23.8%

Entity: Serina Therapeutics, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$0.00	$130.00K	$130.00K	$130.00K	$0.00
Operating Income	Not available	$-24.02M	$-17.82M	$-11.42M	$-5.86M
Net Income	Not available	$-19.18M	$-15.85M	$-11.26M	$-4.81M
EPS (Diluted)	$-0.35	$-1.91	$-1.60	$-1.15	$-0.49
Total Assets	Not available	$6.95M	$12.41M	$8.94M	$6.73M
Total Liabilities	Not available	$6.99M	$10.82M	$7.29M	$5.17M
Cash & Equivalents	Not available	$3.06M	$8.62M	$6.04M	$4.27M
Free Cash Flow OCF − CapEx	Not available	$-18.01M	$-11.98M	$-8.12M	$-4.32M
Shares Outstanding	Not available	10.77M	10.54M	10.14M	9.93M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.